Navigation Links
BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
Date:7/9/2013

BOULDER, Colo., July 8, 2013 /PRNewswire/ -- BiOptix formally announces a unique to the industry research collaboration with the Biophysics Shared Resource Core Facility at the University of Colorado Denver, Anschutz Medical Campus.  The collaboration, which is supported by BiOptix, is offering low cost SPR services for Colorado-based researchers on the new BiOptix 404pi, a next-generation surface plasmon resonance platform designed and built in Colorado.  The BiOptix 404pi provides label-free analysis of protein-protein kinetics as well as protein-small molecule interactions.

"We are proud to partner with and support the Biophysics Shared Resource Facility at the University of Colorado," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix.  "By offering the use of the new BiOptix 404pi to researchers based in Colorado, BiOptix can both support as well as foster scientific research and activity here in our home state."  Researchers from academia as well as industry, who are based in or have principal activities in Colorado, are invited to participate in the program.   

The Biophysics Shared Resource Facility is a user facility owned and operated by the Program in Structural Biology and Biochemistry at the University of Colorado, Denver.  Since opening in 2001, the group has developed resources to study biomolecular structure and thermodynamics through surface plasmon resonance, CD/ORD, ITC, DSC, fluorescence spectroscopy, and analytical ultracentrifugation (AUC).  In addition, the group also offers mass spectroscopy, LC/MS/MS, HPLC and amino acid analysis services.  Additional information about the facility as well as the program supported by BiOptix can be found via the following link:  http://www.ucdenver.edu/academics/colleges/medicalschool/programs/biomol/strucbiocores/biophysics/Pages/biophysicscorefacilities.aspx

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
2. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
3. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
4. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
5. Blue Sky BioServices Expands its Executive Team - Announces Appointment of Ted Marple as President and CEO
6. Concord Medical Announces Launch of Mobile Health Application
7. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
8. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
9. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
10. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
11. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):